Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hepatic radiotherapy plus standard of care in HLA A*02:01 positive metastatic uveal melanoma
2024-519760-40-00Phase 2Authorised
- Sponsor
- Policlinico Gemelli
- Start
- Jul 2025
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of tebentafusp in uveal melanoma (UM) (2 arms), sponsored by Policlinico Gemelli. Primary endpoint: Progression-free survival (PFS) and 6-month PFS rate. Planned start Jul 2025; status: authorised.
02
Drugs
tebentafusp
03
Conditions
uveal melanoma (UM)
Beyond the preview
Go deeper on 2024-519760-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519760-40-00.